Sigilon Therapeutics, Inc.
SGTX · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $730,841 | $392,531 | $147,703 | $212,867 |
| - Cash | $19,621 | $41,255 | $42,066 | $32,925 |
| + Debt | $7,388 | $25,470 | $28,061 | $30,606 |
| Enterprise Value | $718,608 | $376,746 | $133,698 | $210,548 |
| Revenue | $5,900 | $4,858 | $2,644 | $4,252 |
| % Growth | 21.4% | 83.7% | -37.8% | – |
| Gross Profit | $5,900 | $4,858 | $2,644 | $4,252 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$6,886 | -$6,452 | -$4,340 | -$7,749 |
| % Margin | -116.7% | -132.8% | -164.1% | -182.2% |
| Net Income | -$7,506 | -$7,509 | -$5,640 | -$8,919 |
| % Margin | -127.2% | -154.6% | -213.3% | -209.8% |
| EPS Diluted | -0.23 | -0.23 | -0.17 | -0.28 |
| % Growth | 0% | -35.3% | 39.3% | – |
| Operating Cash Flow | -$4,156 | -$11,402 | -$7,217 | -$9,988 |
| Capital Expenditures | -$139 | -$351 | -$25 | -$6 |
| Free Cash Flow | -$4,295 | -$11,753 | -$7,242 | -$9,994 |